NASDAQ

Spruce Biosciences, Inc. (SPRB)

324 Thanks from members

Spruce Biosciences (SPRB) experiences mixed market sentiment driven by its ongoing development of TA-ERT for Sanfilippo Syndrome Type B, navigating timeline shifts, recent capital raises, and a going concern auditor warning.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →